grey market retatrutide ⚠️ BEWARE OF SOLD ONLINE! There are many "miracle" weight loss solutions spreading on social media, but not all are safe. Retatrutide is still undergoing clinical trials and NO FDA APPROVAL Retatrutide and the Grey Market:

Comparison of the Effects of 10 GLP-1 RA and SGLT2 Inhibitor Interventions on Cardiovascular, Mortality, and Kidney Outcomes in Type 2 Diabetes: A Network Meta-Analysis of Large Randomized Trials

A.BunckM

For complete dosing details, see the tirzepatide dosing guide

Comparing Their Molecular Design Although both peptides belong to the same general family, they were engineered with different research objectives

The first head-to-head clinical trial (SURMOUNT-5, published in the New England Journal of Medicine in 2025) showed tirzepatide produced 20.2% average weight loss at 72 weeks compared to 13.7% for semaglutide approximately 47% greater relative weight loss

(2018) Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist